Puma Biotechnology, Inc. (PBYI)
Nasdaq · Pharmaceutical Preparations · Manufacturing · CIK 1401667 · fiscal year ends in Dec
Closing price $10.54 on 29 Oct 2026; 52-week range $4.73 to $11.28.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $231.2M
- Revenue growth
- -2.9%
- Net income, last twelve months
- $26.7M
- Earnings per share
- $0.52
- Gross margin
- 74.8%
- Operating margin
- 13.2%
- Net margin
- 11.6%
- Return on equity
- 19.3%
- Market value
- $538.4M
- Price to earnings
- 20.3x
- Cash
- $36.5M
- Debt
- $0
- Debt to equity
- 0.00
- Shares outstanding
- 51.1M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $228.4M | $37.3M | $31.1M | $0.61 | $41.7M | 10-K filed 26 Feb 2026 |
| FY2024 | 31 Dec 2024 | $230.5M | $31.0M | $30.3M | $0.62 | $38.9M | 10-K filed 27 Feb 2025 |
| FY2023 | 31 Dec 2023 | $235.6M | $32.6M | $21.6M | $0.45 | $26.9M | 10-K filed 29 Feb 2024 |
| FY2022 | 31 Dec 2022 | $228.0M | $23.7M | $2.0K | $0.00 | -$15.8M | 10-K filed 2 Mar 2023 |
| FY2021 | 31 Dec 2021 | $253.2M | $1.3M | -$29.1M | -$0.72 | $20.6M | 10-K filed 3 Mar 2022 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $56.5M | $8.2M | $0.16 |
| Q1 FY2026 | 31 Mar 2026 | $44.8M | -$3.8M | -$0.07 |
| Q4 FY2025 | 31 Dec 2025 | $75.5M | $13.4M | $0.26 |
| Q3 FY2025 | 30 Sep 2025 | $54.5M | $8.8M | $0.17 |
| Q2 FY2025 | 30 Jun 2025 | $52.4M | $5.9M | $0.12 |
| Q1 FY2025 | 31 Mar 2025 | $46.0M | $3.0M | $0.06 |
| Q4 FY2024 | 31 Dec 2024 | $59.1M | $19.3M | $0.39 |
| Q3 FY2024 | 30 Sep 2024 | $80.5M | $20.3M | $0.41 |
Revenue by segment
As the company reports it in the segment note of its annual report.
By product, FY2025
| Segment | Revenue | Share |
|---|---|---|
| Product | $204.1M | 89.4% |
| Royalty | $24.3M | 10.6% |
Company events
The newest 8-K filings of 207 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 6 Aug 2026 | 8-K | Results | 2.02, 9.01 |
| 16 Jun 2026 | 8-K | Shareholder vote | 5.07 |
| 7 May 2026 | 8-K | Results | 2.02, 9.01 |
| 26 Feb 2026 | 8-K | Results | 2.02, 9.01 |
| 6 Nov 2025 | 8-K | Results | 2.02, 9.01 |
| 7 Aug 2025 | 8-K | Results | 2.02, 9.01 |
| 24 Jun 2025 | 8-K | Bylaws or fiscal year change | 5.03, 9.01 |
| 13 Jun 2025 | 8-K | Shareholder vote | 5.07 |
| 9 May 2025 | 8-K | Leadership change | 5.02 |
| 8 May 2025 | 8-K | Results | 2.02, 9.01 |
| 27 Feb 2025 | 8-K | Results | 2.02, 9.01 |
| 7 Nov 2024 | 8-K | Results | 2.02, 9.01 |
Every filing
The newest filings with the SEC of 435 held.
| Filed | Form | Period |
|---|---|---|
| 6 Aug 2026 | 10-Q | 30 Jun 2026 |
| 6 Aug 2026 | 8-K | 6 Aug 2026 |
| 16 Jun 2026 | 8-K | 11 Jun 2026 |
| 7 May 2026 | 10-Q | 31 Mar 2026 |
| 7 May 2026 | 8-K | 7 May 2026 |
| 28 Apr 2026 | DEFA14A | – |
| 28 Apr 2026 | ARS | 31 Dec 2025 |
| 28 Apr 2026 | DEF 14A | 11 Jun 2026 |
| 7 Apr 2026 | PRE 14A | 11 Jun 2026 |
| 26 Feb 2026 | 10-K | 31 Dec 2025 |
| 26 Feb 2026 | 8-K | 26 Feb 2026 |
| 6 Nov 2025 | 10-Q | 30 Sep 2025 |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 14 Sep 2026 | Wilson Troy Edward, Director | Sale under a trading plan | 5,000 | $9.10 | $45.5K | 54,750 | 16 Sep 2026 |
| 14 Sep 2026 | Cesano Alessandra, Director | Sale under a trading plan | 62,150 | $9.12 | $567.0K | 56,700 | 16 Sep 2026 |
| 6 Jul 2026 | Auerbach Alan H, President and CEO | Sale under a trading plan | 44,058 | $8.26 | $364.1K | 7,261,671 | 8 Jul 2026 |
| 6 Jul 2026 | Hunt Douglas M, See Remarks | Sale under a trading plan | 8,460 | $8.26 | $69.9K | 196,841 | 8 Jul 2026 |
| 6 Jul 2026 | Nougues Maximo F, Chief Financial Officer | Sale under a trading plan | 9,386 | $8.26 | $77.6K | 230,637 | 8 Jul 2026 |
| 12 Jun 2026 | Wilson Troy Edward, Director | Sale under a trading plan | 10,800 | $7.20 | $77.7K | 59,750 | 15 Jun 2026 |
| 12 Jun 2026 | Stuglik Brian M, Director | Sale under a trading plan | 8,100 | $7.20 | $58.3K | 113,858 | 15 Jun 2026 |
| 12 Jun 2026 | Senderowicz Adrian, Director | Sale under a trading plan | 27,000 | $7.20 | $194.3K | 27,000 | 15 Jun 2026 |
| 12 Jun 2026 | Moyes Jay M, Director | Sale under a trading plan | 22,000 | $7.22 | $158.8K | 58,322 | 15 Jun 2026 |
| 12 Jun 2026 | Dorval Allison, Director | Sale under a trading plan | 11,610 | $7.20 | $83.6K | 90,780 | 15 Jun 2026 |
| 7 Jan 2026 | Auerbach Alan H, President and CEO | Sale under a trading plan | 18,012 | $5.88 | $105.9K | 7,145,951 | 8 Jan 2026 |
| 7 Jan 2026 | Hunt Douglas M, See Remarks | Sale under a trading plan | 5,014 | $5.88 | $29.5K | 155,907 | 8 Jan 2026 |
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| Filed | Seller | Shares | Value | Planned sale |
|---|---|---|---|---|
| 14 Sep 2026 | WILSON TROY EDWARD, Director | 5,000 | $45.5K | 14 Sep 2026 |
| 14 Sep 2026 | Cesano Alessandra, Director | 62,150 | $565.6K | 14 Sep 2026 |
| 6 Jul 2026 | HUNT DOUGLAS M, Officer | 8,460 | $69.9K | 6 Jul 2026 |
| 6 Jul 2026 | NOUGUES MAXIMO F, Officer | 9,386 | $77.6K | 6 Jul 2026 |
| 6 Jul 2026 | AUERBACH ALAN H, Officer, Director | 44,058 | $364.0K | 6 Jul 2026 |
| 12 Jun 2026 | Stuglik Brian M, Director | 8,100 | $58.8K | 12 Jun 2026 |
| 12 Jun 2026 | WILSON TROY EDWARD, Director | 10,800 | $78.4K | 12 Jun 2026 |
| 12 Jun 2026 | Dorval Allison, Director | 11,610 | $84.3K | 12 Jun 2026 |
| 12 Jun 2026 | MOYES JAY M, Director | 22,000 | $159.7K | 12 Jun 2026 |
| 12 Jun 2026 | Senderowicz Adrian, Director | 27,000 | $196.0K | 12 Jun 2026 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 6 Oct 2026 | Alan H. Auerbach | 13D amended | 16% | 8.6M |
| 27 Mar 2026 | The Vanguard Group | 13G amended | 0% | 0 |
Trades by members of the House
From each member's periodic transaction report.
| Traded | Member | Type | Amount | Disclosed |
|---|---|---|---|---|
| 15 May 2019 | Donna Shalala (FL27) | Sale | $1,001 - $15,000 | 27 Apr 2020 |
| 23 Jan 2019 | Donna Shalala (FL27) | Purchase | $1,001 - $15,000 | 27 Apr 2020 |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 4.5M | +6.46% | 12.88 |
| 30 Sep 2026 | 4.3M | -1.27% | 14.02 |
| 15 Sep 2026 | 4.3M | +1.06% | 13.8 |
| 31 Aug 2026 | 4.3M | +2.56% | 15.62 |
| 14 Aug 2026 | 4.2M | +1% | 11.39 |
| 31 Jul 2026 | 4.1M | +5.55% | 13.89 |
| 15 Jul 2026 | 3.9M | +7.74% | 10.65 |
| 30 Jun 2026 | 3.6M | -1.9% | 8.47 |
Funds that hold it
From each fund's latest Form 13F.
175 funds held it at 30 Jun 2026: 79 added and 51 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| Acorn Capital Advisors, LLC | 4,131,299 | $33.5M | 0 |
| BlackRock, Inc. | 3,804,736 | $30.9M | +205,784 |
| American Century Companies Inc. | 2,319,996 | $18.8M | +403,650 |
| Acadian Asset Management LLC | 2,053,523 | $16.6M | +11,764 |
| Renaissance Technologies LLC | 1,836,213 | $14.9M | -106,200 |
| Vanguard Capital Management LLC | 1,835,643 | $14.9M | +17,962 |
| Vanguard Portfolio Management LLC | 1,825,599 | $14.8M | +90,950 |
| LSV Asset Management | 1,617,981 | $13.1M | +435,113 |
| Dimensional Fund Advisors LP | 1,518,014 | $12.3M | +81,908 |
| Geode Capital Management, LLC | 1,339,405 | $10.9M | +322,063 |
Peers
Companies in the same industry.
- Eli Lilly & Co. (LLY): revenue $86.5B, market value $1.29T
- Johnson & Johnson (JNJ): revenue $99.3B, market value $662.4B
- AbbVie Inc. (ABBV): revenue $64.4B, market value $513.9B
- Merck & Co., Inc. (MRK): revenue $66.6B, market value $361.0B
- Novartis AG (NVS): revenue $54.5B, market value $307.3B
- AstraZeneca PLC (AZN): revenue $58.7B, market value $270.6B
- Abbott Laboratories (ABT): revenue $46.6B, market value $180.9B
- Novo Nordisk A/S (NVO): revenue $46.8B, market value $174.8B
- Pfizer Inc. (PFE): revenue $63.7B, market value $170.7B
- Vertex Pharmaceuticals Inc. (VRTX): revenue $12.6B, market value $136.8B